Rossella Ribolla

Minimal residual disease assessment by multiparameter flow cytometry in transplant-eligible myeloma in the EMN02/HOVON 95 MM trial

Stefania Oliva, Davine Hofste op Bruinink, Lucie Říhová et al. · Blood Cancer Journal · 2021 · 47 citations · Full text

Medicine, Hematology, Oncology +17

Transplant eligibility in elderly multiple myeloma patients: Prospective external validation of the international myeloma working group frailty score and comparison with clinical judgment and other comorbidity scores in unselected patients aged 65‐75 years

Angelo Belotti, Rossella Ribolla, Valeria Cancelli et al. · American Journal of Hematology · 2020 · 39 citations · Full text

Medicine, Hematology, Oncology +15

Predictive role of diffusion‐weighted whole‐body MRI (DW‐MRI) imaging response according to MY‐RADS criteria after autologous stem cell transplantation in patients with multiple myeloma and combined evaluation with MRD assessment by flow cytometry

Angelo Belotti, Rossella Ribolla, Valeria Cancelli et al. · Cancer Medicine · 2021 · 39 citations · Full text

Medicine, Hematology, Radiology +17

Postremission sequential monitoring of minimal residual disease by <scp>WT</scp>1 Q‐<scp>PCR</scp> and multiparametric flow cytometry assessment predicts relapse and may help to address risk‐adapted therapy in acute myeloid leukemia patients

Michele Malagola, Cristina Skert, Erika Borlenghi et al. · Cancer Medicine · 2015 · 33 citations · Full text

Medicine, Hematology, Oncology +16

Peripheral Blood WT1 Expression Predicts Relapse in AML Patients Undergoing Allogeneic Stem Cell Transplantation

Michele Malagola, Cristina Skert, Giuseppina Ruggeri et al. · BioMed Research International · 2014 · 25 citations · Full text

Medicine, Hematology, Oncology +11